Annual report pursuant to Section 13 and 15(d)

Note 13 - Concentration of credit risk

v3.19.1
Note 13 - Concentration of credit risk
12 Months Ended
Dec. 31, 2018
Notes  
Note 13 - Concentration of credit risk

Note 13 – Concentration of credit risk

 

The Company has a significant portion of its assets invested in G Farma Entities. These investments include the notes receivable and the 3.84% equity interest in G Farma Equity Entities described in Note 9, the finance leases receivable described in Note 10, and the contractual interest in legal recovery described in Note 12. At December 31, 2018 and 2017, these assets represent 27% and 19% of the consolidated total assets of the Company, respectively.

 

The Company closely monitors each investment based on known and inherent risks in our investments which include financial results, satisfying scheduled payments and compliance with financial covenants, adverse situations that may affect the borrower’s ability to repay, estimated value of underlying collateral and current economic conditions. No impairments or reserves are recorded at December 31, 2018 and 2017 for these investments.